Fig1 (Image 1)
Sildenafil Powder, For Suspension
Product Images NDC 0591-4050
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 0591-4050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig9 (Image 10)
Fig10 (Image 11)
This appears to be a medical study evaluating the effectiveness of Sildenafil (20 mg TID) in treating patients with pulmonary arterial hypertension (PAH) based on their baseline walk distance and functional capacity. The study compared the results of patients who were given Sildenafil versus a placebo and measured their 6-minute walking distance post-treatment. The text provides a table with various measurements including ages, PAP, and PVRI values. The chart also shows a graph with placebo-corrected changes in 6-minute walking distances (in meters) for the groups.*
Fig11 (Image 12)
Fig12 (Image 13)
This text appears to be a graph showing the mean change from baseline for different treatments at different weeks of a study up to week 12. It is not possible to discern the exact details without the visual aid of the graph.*
Ifu-fig-a (Image 14)
Ifu-fig-b (Image 15)
Ifu-fig-c (Image 16)
Ifu-fig-d (Image 17)
Ifu-fig-e (Image 18)
Ifu-fig-f (Image 19)
Fig2 (Image 2)
Ifu-fig-g (Image 20)
Prf 4 Pdp (Image 21)
This is a medication label for Sildenafil - Sildenafil oral suspension. The recommended storage temperature before reconstitution is below 30°C/86°F. After reconstitution, it should be stored either below 30°C/86°F or in a refrigerator at 2-8°C (36-46°F). The suspension contains 10mg of Sildenafil per 3mL and comes in a grape flavor. The recommended dosage should be prescribed by a doctor. The label provides instructions on how to reconstitute the suspension using water, and warns to discard any unused portions after the recommended 60 days of use. The manufacturer is listed as To Pramcentss SA, and the product is for oral use only.*
Fig3 (Image 3)
Fig4 (Image 4)
Fig5 (Image 5)
Fig6 (Image 6)
This appears to be a table showing estimated cumulative mortality rates (%) for individuals exposed to different doses of a certain substance over time. There are three different dose levels: high, medium, and low. The table shows the mortality rates for each dosage level over a period of five years.*
Formula (Image 7)
Fig7 (Image 8)
The table provides recommendations for drug-dose adjustments for interacting medications. The drugs listed, such as Atorvastatin and Oral Contraceptives, do not require adjustments for dosages. However, drugs like Ritonavir are not recommended to be co-administered, as it can cause side effects. In addition, the last line indicates that adding sildenafil to bosentan therapy does not lead to any benefits for exercise capacity.*
Fig8 (Image 9)
This is a list of drugs and their respective recommendation for dose adjustment when interacting with other drugs. Most of the drugs require no adjustment except for Ritonavir, which is not recommended for co-administration. The text also contains a chart showing the change relative to the interacting drug alone that ranges from 0.5 to 2.0. There is a note about the benefit of adding sildenafil to bosentan therapy for exercise capacity, and the effect of ritonavir on sildenafil PK.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
